Key Studies in Breast, Gynecologic, Renal Cell, Urothelial, Lung, Hepatobiliary, and Skin Cancers: CCO Independent Conference Highlights of the 2022 ESMO Congress
  • CME

September 9-13, 2022; Paris, France
Gain expert perspectives on the most clinically relevant data on breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress.
Nicoletta Colombo, MD
Robert Motzer, MD
person default
Sapna P. Patel, MD
David Planchard, MD, PhD
Elizabeth R. Plimack, MD, MS
Rachna Shroff, MD, MS
Sara Tolaney, MD, MPH
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: November 14, 2022 Expiration: November 13, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with cancer
  • Identify subpopulations of patients with cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Evaluate new data on novel agents and therapeutic approaches for patients with cancer
  • Appraise how new trial findings might affect treatment of cancer clinical practice in the future

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Exelixis, Inc.
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Nicoletta Colombo, MD

Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Nicoletta Colombo, MD:consultant/advisor/speaker: AstraZeneca, Clovis Oncology, Eisai, GlaxoSmithKline, Immunogen, Mersana, MSD/Merck, Novartis, Nuvation Bio, Onxerna, Pfizer, Pieris, Roche; researcher: AstraZeneca, Roche.
Robert Motzer, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Robert Motzer, MD:consultant: Aveo, Eisai, Exelixis, Genentech, Merck, Roche.
Rachna Shroff, MD, MS

Assistant Professor of Medicine
Chief
, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Rachna Shroff, MD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, CAMI, Clovis, Genentech, Incyte, QED; researcher: Bayer, Bristol-Myers Squibb, Exelixis, IMV Inc., Loxo, Merck, Novocure, Nucana, Pieris, QED, Rafael, Seagen, Taiho, Zymeworks.
Sapna P. Patel, MD

Assistant Professor
Director of the Uveal Melanoma Program
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Chair, SWOG Melanoma Committee
SWOG Cancer Research Network

Sapna P. Patel, MD: consultant/advisor/speaker: Bristol-Myers Squibb, Castle Biosciences, Delcath, Immatics, Immunocore, Merck, Novartis, Reata, TriSalus Life Sciences; stock/stock options: Amgen, Pfizer; other financial or material support: Bristol-Myers Squibb, Cardinal Health, Foghorn Therapeutics, Ideaya, InxMed, Merck, Novartis, NCI, Provectus, Seagen, Syntrix Bio, TriSalus Life Sciences.
David Planchard, MD, PhD

Head of Thoracic Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

David Planchard, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Novartis, Pfizer, Roche.
Elizabeth R. Plimack, MD, MS

Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS: consultant/advisor/speaker: Astellas, AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, EMD Serono, Exelixis, IMV Inc., Infinity Pharma, Janssen, MEI, Merck, Natera, Pfizer, Regeneron, Seagen; researcher: Astellas, Bristol-Myers Squibb, Genentech, Merck.
Sara Tolaney, MD, MPH

Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara M. Tolaney, MD, MPH:consultant/advisor: 4D Pharma, ARC Therapeutics, AstraZeneca, Athenex, BeyondSpring, Blueprint Medicines, Bristol-Myers Squibb, Certara, Chugai, CytomX, Daiichi Sankyo, Eisai, Ellipses, Genentech/Roche, Gilead, Infinity, Lilly, Merck, Mersana, Myovant, Novartis, Odonate, OncoSec Medical, OncXerna, Pfizer, Reveal Genomics, Sanofi, Seagen, Umoja, Zentalis, Zetagen, Zymeworks; researcher: AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Pfizer, Sanofi, Seagen.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for global physicians and other healthcare professionals who care for patients with cancer.

Goal

The goal of this activity is to improve the understanding of healthcare professionals globally on recent practice-changing clinical data on the treatment of patients with cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 14, 2022, through November 13, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Stacey Stein, MD, on systemic therapy for advanced hepatocellular carcinoma, including most recent clinical data on first-line and second-line treatment options in this Clinical Care Options (CCO) text module

Stacey Stein, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 1, 2023 Expired: January 31, 2024

Read expert advice about the importance of managing adjuvant abemaciclib adverse events in early breast cancer, from Clinical Care Options (CCO)

Julia LaBarbera, MSN, RN, AGACNP-BC Released: January 31, 2023

Mark Pegram, MD, and Sara Tolaney, MD, MPH, discuss treatment and optimal management approaches for patients with TNBC, from Clinical Care Options (CCO)

Mark Pegram, MD Sara Tolaney, MD, MPH Released: January 31, 2023

Downloadable slideset from a text module on systemic therapies for advanced hepatocellular carcinoma, from Clinical Care Options (CCO)

Stacey Stein, MD Released: January 27, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings